Evidence map›Paper›PMID 16757972›Full record

ArticleBone marrow transplantation2006

EBMT activity survey 2004 and changes in disease indication over the past 15 years.

A Gratwohl, H Baldomero, K Frauendorfer, A Urbano-Ispizua, Joint Accreditation Committee, International Society for Cellular Therapy, European Group for Blood and Marrow Transplantation

Abstract readHistorical ArticleMulticenter Study
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Multisite Randomized Trial of Inpatient Palliative Care Intervention for Patients Undergoing Hematopoietic Stem Cell Transplantation.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025
    Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Sexual Health in Hematopoietic Stem Cell Transplantation Survivors.Journal of the National Comprehensive Cancer Network : JNCCN · 2025
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Palliative and End-of-Life Care for Patients With Hematologic Malignancies.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020
    Review
  18. Article
  19. Article
  20. Hematopoietic SCT in Iranian children 1991-2012.Bone marrow transplantation · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

A GratwohlDivision of Hematology, Department of Internal Medicine, University Hospital Basel, Petersgraben 4, CH-4021 Basel, Switzerland. hematology@uhbs.ch
H Baldomero
K Frauendorfer
A Urbano-Ispizua
Joint Accreditation Committee, International Society for Cellular Therapy
European Group for Blood and Marrow Transplantation

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This fifteenth annual European Group for Blood and Marrow Transplantation activity report lists the transplant activity in Europe in 2004 and documents the changes in indication over the past 15 years. In 2004, there were 22 216 first hematopoetic stem cells (HSCT), 7407 allogeneic (33%), 14 809 autologous (67%) and 4378 additional re- or multiple transplants reported from 592 centres in 38 European and five affiliated countries. Main indications were leukemias (7045 (32%; 78% allogeneic)); lymphomas (12 310 (55%; 94% autologous)); solid tumors (1759 (8%; 93% autologous)) and nonmalignant disorders (1015 (5%; 92% allogeneic)). In comparison, 145 teams from 20 countries performed 4234 HSCT (2137 allogeneic, 50%; 2097 autologous, 50%) in 1990. The overall increase was accompanied by major changes. Stem cell source changed from bone marrow to peripheral blood. More than one-third of allogeneic HSCT are now from unrelated donors. Reduced intensity conditioning is employed for one-third of allogeneic HSCT. Leukemias for allogeneic and lymphoproliferative disorders for autologous HSCT continue to increase. The decline in HSCT for chronic myeloid leukemia appears to level off for the first time since 1999. These data are informative for patient counselling and decision making for health care professionals.

Indexed as

Health Care SurveysHematopoietic Stem Cell TransplantationTissue DonorsTransplantation ConditioningEuropeFemaleHistory, 20th CenturyHistory, 21st CenturyHumansMaleNeoplasmsRetrospective StudiesTransplantation, AutologousTransplantation, Homologous

Identifiers

PMID16757972

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.